Also categorized in Drug:
Treatment of chronic graft versus host disease with bortezomib.
x hide permanently

PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

ncbi.nlm.nih.gov

PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

Mol Cancer Ther. 2018 Feb 13;:

Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

Mentions: Treatment Relapse Refractory